U.S. markets closed
  • S&P 500

    4,076.57
    -3.54 (-0.09%)
     
  • Dow 30

    34,395.01
    -194.76 (-0.56%)
     
  • Nasdaq

    11,482.45
    +14.45 (+0.13%)
     
  • Russell 2000

    1,881.68
    -4.90 (-0.26%)
     
  • Crude Oil

    81.16
    -0.06 (-0.07%)
     
  • Gold

    1,814.70
    -0.50 (-0.03%)
     
  • Silver

    22.90
    +0.06 (+0.26%)
     
  • EUR/USD

    1.0513
    -0.0015 (-0.15%)
     
  • 10-Yr Bond

    3.5290
    -0.1740 (-4.70%)
     
  • GBP/USD

    1.2236
    -0.0021 (-0.17%)
     
  • USD/JPY

    135.4700
    +0.1640 (+0.12%)
     
  • BTC-USD

    16,988.26
    -180.25 (-1.05%)
     
  • CMC Crypto 200

    403.07
    -3.08 (-0.76%)
     
  • FTSE 100

    7,558.49
    -14.56 (-0.19%)
     
  • Nikkei 225

    27,819.47
    -406.61 (-1.44%)
     

Could This Biosimilar Drug Candidate Be a Hit for Novartis?

Could This Biosimilar Drug Candidate Be a Hit for Novartis?

On Sept. 19, Novartis (NYSE: NVS) shared positive news with investors regarding the clinical trial results for its biosimilar drug candidate to Amgen's (NASDAQ: AMGN) osteoporosis medicine Prolia. With Prolia set to lose exclusivity in the U.S. in 2025, Novartis could be close to booking some revenue from its biosimilar drug. Let's go over the outcome of the clinical trial and the U.S. osteoporosis market to figure this out.